ArticleBreast cancer research : BCR2017
Article in Breast cancer research : BCR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Joint EANM-SNMMI guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2024Guideline
- PET-Derived Radiomics and Artificial Intelligence in Breast Cancer: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2022Pooled it
- Amino acid tracers in PET imaging of diffuse low-grade gliomas: a systematic review of preoperative applications.Acta neurochirurgica · 2018Pooled it
- The use of 3'-deoxy-3'-Annals of nuclear medicine · 2019Trial
- Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study.Scientific reports · 2018Trial
- Whole-brain metabolic activity on pretreatment [18 F]FDG PET/CT provides prognostic information beyond metabolic tumour burden in patients with breast cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Relationship Between [European journal of breast health · 2025Article
- Article
- BaselineLa Radiologia medica · 2025Article
- Prediction of the prognosis of liver iron burden within two years after hematopoietic stem cell transplantation based on multimodal MRI-based radiomics model.Frontiers in medicine · 2025Article
- A PET-Surrogate Signature for the Interrogation of the Metabolic Status of Breast Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Utility of positron emission tomography for determination of axillary metastasis of breast cancer.Turkish journal of surgery · 2023Article
- Article
- Prognostic significance of pretreatmentBreast cancer research and treatment · 2023Article
- α- and β-Genotyping of Thalassemia Patients Based on a Multimodal Liver MRI Radiomics Model: A Preliminary Study in Two Centers.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Article
- Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy.Journal of breast cancer · 2022Article
- Radiomic and Volumetric Measurements as Clinical Trial Endpoints-A Comprehensive Review.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated the value of some clinicopathological parameters and 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography (
methodsFDG-PET/CT indices and clinicopathological parameters were assessed before neoadjuvant chemotherapy (NAC). After completion of chemotherapy, all patients had breast surgery with axillary lymph node dissection, followed by radiation therapy and endocrine therapy for 5 years. EFS was estimated using the Kaplan-Meier method. A Cox proportional hazard regression model was used for multivariate analysis.
resultsOne hundred forty-three consecutive patients with stage II-III ER+/HER2- BC and without distant metastases at baseline PET were included. High standardized uptake values (SUVs), were associated with shorter EFS (HR = 3.51, P < 0.01 for SUV
conclusionsBaseline PET parameters measured before neoadjuvant treatment have prognostic values in ER+/HER2- locally advanced breast cancer patients. After multivariate analysis, metabolically active tumor volume remains significant while textural analysis of PET images is not of added value. Considering histopathological parameters, our study shows that patients with PR-negative or lobular invasive tumor have poorer prognosis than patients with PR-positive or ductal carcinoma, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.